Matthew Gavidia

September 18, 2021

Treatment of guselkumab was found to be safe and effective in improving health-related quality-of-life (HRQOL) and skin manifestations of patients with moderate to severe psoriasis in a real-world setting.

September 17, 2021

Children who experience lower respiratory tract infections early in their lives were shown to be at significantly greater risk of developing obstructive sleep apnea in the first 5 years of life.

September 17, 2021

Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.

September 15, 2021

Medicare beneficiaries with psoriasis and psoriatic arthritis were found to pay high annual out-of-pocket (OOP) costs for treatment, which researchers attributed to rising drug prices and reliance on co-insurance for patient cost-sharing.

September 15, 2021

People with both ophthalmic and systemic conditions were found to be at higher risk of dementia compared with those with only 1 such condition. Some ophthalmic conditions—age-related macular degeneration, cataract, and diabetes-related eye disease—also increased risk on their own.

September 14, 2021

Eating or drinking less than 1 hour before bedtime was associated with increased risk of wake after sleep onset, a key symptom of chronic insomnia that significantly correlates with poor sleep quality.

September 14, 2021

Psychological and emotional needs specific to populations with cancer are often overlooked in clinical research, including those of adolescents, young adults, immigrants, and people of lower socioeconomic status.

September 11, 2021

Discontinued use and high dosage of alpha-glucosidase inhibitors in combination with metformin was shown to increase risk of psoriasis and psoriatic arthritis in patients with type 2 diabetes compared with those given only metformin.

September 10, 2021

Students in grades 3 to 7 who were given eyeglasses as part of a school-based vision program were found to achieve better reading scores and exhibit improved academic achievement over 1 year.

September 09, 2021

Findings of a phase 2b study indicated that use of tildrakizumab was associated with significant improvements in joint and skin manifestations of patients with psoriatic arthritis (PsA), although improvement in symptoms of dactylitis and enthesitis were not observed.